MedTrace Logo

Identification of Null Allelic Variant of CYP2C8 In A Korean Population

NCT01872780 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2013-06-07

No results posted yet for this study

Summary

The genotype profile of CYP2C8 was analyzed in a Korean population. Frequency in multi-ethnic population and in vivo functionality of novel null allelic CYP2C8 variant were evaluated.

Conditions

  • Healthy

Interventions

DRUG

Rosiglitazone

single oral administration of 4mg of rosiglitazone

GENETIC

CYP2C8 genotype

CYP2C8\*11.

Sponsors & Collaborators

  • Inje University

    lead OTHER

Principal Investigators

  • Jae-Gook Shin, MD, PhD · Inje University

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-08-31
Primary Completion
2009-02-28
Completion
2009-03-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01872780 on ClinicalTrials.gov